# Marty Makary Type: Person Source: GetYourBrief — https://getyourbrief.com/entity/marty-makary Canonical HTML page: https://getyourbrief.com/entity/marty-makary ## Timeline - **2026-08-19**: Trump announces Overton nomination — Trump posts the nomination on social media, calling Overton a ROCKSTAR and quoting HHS Secretary Kennedy: Heidi is ALWAYS RIGHT. - **2026-08-19**: Trump announces Heidi Overton as FDA Commissioner nominee — President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation. - **2026-08-19**: Trump announces Heidi Overton as FDA Commissioner nominee — President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation. - **2026-08-18**: Administration still interviewing FDA candidates — A senior administration official says the search remains open the day before the announcement; Brad Wenstrup and Kyle Diamantas have already declined. - **2026-08-10**: Trump signs childhood-vaccination executive order — Overton stands at Trump's side and urges blue states to adopt the administration's gold standard recommendations, which many physicians say lack scientific support. - **2026-05**: Marty Makary resigns as FDA commissioner — Makary steps down after clashes with the White House, creating the vacancy Overton would fill. - **2026-05**: Marty Makary resigns as FDA Commissioner — The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots. - **2026-05**: Marty Makary resigns as FDA Commissioner — The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots. - **2026-03-11**: Document Request — Expected date for formal requests for internal FDA communications regarding DMD drug applications. - **2026-03-11**: Initial Inquiry — The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations. - **2026-03-10**: Investigation Announced — Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process. - **2026-03-10**: Commissioner Consultation — Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy. - **2026-03-10**: Investigation Announced — Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications. - **2026-03-10**: Commissioner Meeting — Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections. ## Recent coverage (9 stories, network-wide) ### Overton's FDA Pick: 3 Regulatory Fault Lines for Health Tech 2026-08-20 00:44:20 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2 For health IT, medical device and telehealth leaders, Overton's nomination signals a period of regulatory uncertainty. Her backing of MAHA and most favored nation drug pricing could reshape digital health evidence standards, diagnostics oversight and vaccine-adjacent software, even as deregulatory forces promise faster approvals. Confirmation will test how the FDA balances innovation with public health safeguards. Full story: https://gethealthbrief.com/story/overton-fda-health-tech-regulatory-fault-lines ### Overton FDA Nomination: 4 Biopharma Risks From Drug Pricing to Vaccines 2026-08-20 00:44:07 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2 For biotech and pharma executives, Overton's nomination combines Trump's favored-nation drug pricing push with RFK Jr.'s vaccine skepticism and unfinished reviews of antidepressants and COVID shots. The result could compress margins while opening faster approval pathways for innovation. Investors should watch how she navigates evidence standards and political priorities at the FDA. Full story: https://getbiobrief.com/story/overton-fda-biopharma-drug-pricing-vaccine-risks ### Heidi Overton, Trump's 3rd FDA Pick, Faces Senate Confirmation Fight 2026-08-19 18:18:12 · Sector: legal · Sentiment: Neutral · Impact: 7/10 · Sources: 2 Trump's nomination of Heidi Overton to lead the FDA sets up a high-stakes Senate confirmation and a new era of administrative rulemaking on vaccines and food safety. Regulatory lawyers are watching the precedent set by the narrow CDC confirmation of Erica Schwartz and the legal vulnerabilities in the administration's childhood-vaccination executive order. Full story: https://getlegalbrief.com/story/heidi-overton-fda-nomination-senate-confirmation-legal ### Trump's 3rd FDA Pick Steps In Amid Cyclospora Food-Safety Outbreak 2026-08-19 18:17:55 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2 A White House health-policy aide with a hand in the childhood vaccine-schedule rewrite is tapped to run the FDA during a multistate cyclospora outbreak. Health systems and public-health officials now weigh the operational impact of leadership churn and a nominee whose recommendations physicians say lack scientific support. Full story: https://gethealthbrief.com/story/heidi-overton-fda-cyclospora-food-safety-health ### Trump's 3rd-Choice FDA Pick Overton Shifts Pharma's Regulatory Outlook 2026-08-19 18:17:37 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2 Biopharma's key regulator is set to change hands as Trump nominates Heidi Overton, architect of drug-pricing negotiations and vaccine-schedule revisions. Developers and investors are assessing what her confirmation means for approval timelines, pricing pressure, and regulatory predictability. Full story: https://getbiobrief.com/story/heidi-overton-fda-pharma-regulatory-outlook-bio ### GOP Senator Probes FDA Over Rare Disease Drug Rejections 2026-03-10 22:18:47 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards. Full story: https://getbiobrief.com/story/ron-johnson-fda-rare-disease-investigation ### Senator Ron Johnson Launches Investigation Into FDA Rare Disease Drug Denials 2026-03-10 22:18:15 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA's handling of biologic therapy applications for rare diseases, specifically targeting Duchenne muscular dystrophy. The probe follows a direct consultation with FDA Commissioner Marty Makary regarding perceived regulatory barriers for life-saving treatments. Full story: https://gethealthbrief.com/story/ron-johnson-fda-rare-disease-investigation ### Senator Johnson Launches Investigation into FDA Rare Disease Drug Denials 2026-03-10 22:17:42 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions. Full story: https://getlegalbrief.com/story/senator-johnson-fda-rare-disease-investigation ### FDA Commissioner Pushes for New Antidepressant Warnings via Controversial Hire 2026-03-04 20:16:14 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry. Full story: https://getbiobrief.com/story/fda-makary-hoeg-antidepressant-warning-controversy --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.